Company news
Bioversys Ag (SIX:BIOV) news
Bioversys Ag news releases on 6ix. Latest, Sep 9, 2026: BioVersys reports half-year 2026 results: BV100 pivotal RIV-TARGET trial actively recruiting…
Press releases & updates
BioVersys reports half-year 2026 results: BV100 pivotal RIV-TARGET trial actively recruiting, alpibectir Phase 2b/c underway, operations funded into 2028
September 9, 2026
BioVersys to Present at H.C. Wainwright 28th Annual Global Investment Conference
September 3, 2026
BioVersys granted Fast-Track Designation from US FDA for BV100
September 2, 2026
BioVersys to report its half-year 2026 financial results, provide a business update and host a conference call
August 26, 2026
BioVersys announces approval of all Board Proposals at Annual General Meeting of Shareholders
April 30, 2026
BioVersys completes BV100 Phase 1 clinical trial in China
April 22, 2026
BioVersys Announces First Patient First Visit in HABP/VABP Pivotal Phase 3 RIV-TARGET Trial of BV100
April 16, 2026
BioVersys to Present Data on Clinical and Preclinical Pipeline Programs at ESCMID Global 2026
April 15, 2026
Data Published in Nature Communications Highlights Unique Mechanism of Action of Alpibectir in Combination with Ethionamide (AlpE)
April 13, 2026
BioVersys Issues Invitation to its 2026 Annual General Meeting of Shareholders
April 7, 2026
BioVersys Appoints Anca Cighi as Head of Investor Relations and Communications
April 2, 2026
BioVersys Strengthens Ansamycin Platform and NTM Research Through Collaboration and License Agreement with Hackensack Meridian Health
March 31, 2026
BioVersys Reports Corporate Highlights and Financial Results for the Full Year 2025
March 18, 2026
BioVersys Receives Green Light from US FDA for BV100 HABP/VABP Phase 3 Pivotal Trial Start
March 16, 2026
BioVersys Announces First Patient Dosed in Phase 2b Clinical Trial of AlpE in Pulmonary Tuberculosis
March 12, 2026
BioVersys to Report Its Full Year 2025 Financial Results, Provide a Business Update and Host a Conference Call
March 5, 2026
BioVersys Announces Publication of BV100 Phase 1 Clinical Data in Journal of Antimicrobial Agents and Chemotherapy
March 4, 2026
BioVersys and Partners’ Phase 2a Tuberculosis Trial Results Published in New England Journal of Medicine
February 19, 2026
BioVersys Announces BV100 Phase 3 Initiation and Provides a Business Update
December 11, 2025
BioVersys BV100 Phase 2b to be Conducted Via Wellcome Funded Trial Network
November 10, 2025
Bioversys Reports Corporate Highlights and Key Financials For the First Half 2025
September 10, 2025
BioVersys Receives EMA Orphan Designation for the Combination of Alpibectir and Ethionamide for the Treatment of Tuberculosis
August 27, 2025
BioVersys and Shionogi Enter Into Global Research Collaboration For Broad-Spectrum Non-Tuberculous Mycobacteria (NTM) Clinical Candidate
July 2, 2025
BioVersys Reports Corporate Highlights and Key Financials for the Full Year 2024
March 26, 2025